Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression

Multiple Sclerosis Journal

Volumn 19, Issue 12, 2013, Pages 1580-1586

  Steinvorth, Simon M ^a   Röver, Christian ^a   Schneider, Simon ^a   Nicholas, Richard ^b   Straube, Sebastian ^a   Friede, Tim ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

annualised relapse rate; baseline characteristics; clinical study design; eligibility criteria; meta analysis; meta regression; Multiple sclerosis; placebo group; relapse; systematic review

Indexed keywords

ADULT; DISEASE COURSE; FEMALE; HUMAN; MALE; META ANALYSIS; METHODOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORGANIZATION AND MANAGEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA;

ADULT; DISEASE PROGRESSION; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESEARCH DESIGN;

EID: 84885768838     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513481009     Document Type: Article

References (17)

1. Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996 ; 46: 907-911
3. Nicholas R, Friede T. Considerations in the design of clinical trials for relapsing multiple sclerosis. Clin Invest. 2012 ; 2 (11). 1073-1083
4. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis, www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003485.pdf (2006, accessed 10 September 2012).
5. Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler. 2010 ; 16: 1414-1421
6. Nicholas R, Straube S, Schmidli H, et al. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler J. 2011 ; 17: 1211-1217
7. Nicholas R, Straube S, Schmidli H, et al. Time-patterns of annualized relapse rates in randomized placebo- controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis. Multe Scler J. 2012 ; 18: 1290-1296
8. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996 ; 17: 1-12
9. HigginsJPTGreenS (eds). Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration, www.cochrane-handbook. org (2011, accessed 26 February 2013).
10. Clisant S, Clermont A, Adenis A, et al. Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trials: Illustration over a 20-year period. Contemp Clin Trials. 2012 ; 33: 459
11. Stellmann J-P, Neuhaus A, Herich L, et al. Placebo cohorts in phase-3 MS treatment trials - Predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS ONE. 2012 ; 7: e50347
12. Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1368-1374
13. Martínez-Yélamos S, Martínez-Yélamos A, Martín Ozaeta G, et al. Regression to the mean in multiple sclerosis. Mult Scler. 2006 ; 12: 826-829
14. Kappos L, O'Connor PW, Polman CH, et al. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. J Neurol. 2013 ;:
15. Signori A, Baccino A, Sormani MP. The quality of reports of randomized trials in multiple sclerosis: A review. Mult Scler J. 2012 ; 18: 776-781
16. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010 ; 9: 520-532
17. Held U, Heigenhauser L, Shang C, et al. Predictors of relapse rate in MS clinical trials. Neurology. 2005 ; 65: 1769-1773